PM

#45
Philip Morris International Inc Common Stock
175.4 5 USD
-1.77%
Secteur: Consommateur Défensif
Base: USD
Devise de Profit: USD
Range quotidien
174.91
177.80
Range Annuel
142.11
193.05
Changement quotidien
-1.77%
Changement Mensuel
+7.35%
Evolution sur 6 mois
+11.62%
Changement Annuel
-1.44%
Clôture Précédente
178.6 2
Open
177.2 5
Low
174.9 1
High
177.8 0
Volume
395
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 273.45 B
  • Employee 85 K
  • Founded N/A
  • CEO Jacek Olczak
  • Website www.pmi.com
  • Headquarter Virginia, United States
  • FIGI BBG000J2XL74
  • Industry Tabac
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
22.09
ratio cours/chiffre d'affaires
6.15
Dividende par action
5.64
Rendement du dividende (%)
3.52

Philip Morris International Inc Common Stock

Philip Morris International Inc. is a tobacco company, with products sold in over 180 countries. Marlboro is PMI’s most recognized brand, but in the last quarter of 2023, Iqos generated the greatest revenue. Philip Morris International is often referred to as one of the companies comprising Big Tobacco. The company ranked No. 121 in the 2025 Fortune 500 list of the largest US corporations by total revenue. The company originated in 1847 in London, but Philip Morris International itself was established in 1987 as an operating company of Philip Morris Companies Inc. In 2003, Philip Morris Companies changed its name to Altria Group. In March 2008, PMI was spun off from Altria and has been an entirely separate entity since then. Philip Morris USA, a subsidiary of PMI's former parent, keeps ownership of the Philip Morris brands for the US market. The company's legal seat is in Stamford, Connecticut. PMI's operational headquarters are in Lausanne, Switzerland. With tobacco being addictive and a leading cause of preventable death globally, the company has faced litigation and regulatory measures from governments and has been the subject of scrutiny by the World Health Organization.

Nouvelles